Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q2 Losses Up on Spinout-Related Expenses

Premium

RXi Pharmaceuticals this week released its second-quarter financial results, posting a surge in losses tied to its spinout from former parent firm Galena Biopharma (GSN 5/10/2012).

For the three-month period ended June 30, RXi's net loss jumped to $17.2 million, or $0.13 a share, from a year-ago loss of $1.9 million, or $0.05 a share. According to the company, the increase was largely the result of a $9.6 million non-cash dividend “relating to the beneficial conversion feature as a result of the issuance of convertible preferred stock” in late April when Galena sold 83 percent of RXi to institutional shareholders.

RXi's research and development spending soared to $6.9 million from $1.8 million during the same period last year, a rise in part related to costs associated with the acquisition of patent and technology rights during the spin-off process.

General and administrative costs, meantime, fell to $700,000 from $1 million.

At the end of the second quarter, RXi had cash and cash equivalents totaling $7.6 million, which it said should be sufficient to fund operations into the second quarter of next year.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.